Orikami participates in the Renal Lifecycle Trial of the University Medical Centre Groningen (UMCG)
The Renal Lifecycle Trial is a large global clinical trial initiated by the UMCG that investigates the effect of the drug Dapagliflozin on renal and cardiovascular diseases in patients with severe chronic kidney disease, such as patients on dialysis or living with a kidney graft. The study is mainly funded by the Dutch Kidney Foundation.
Orikami supports this study with its proprietary cognition measurements. Together with more than 80 hospitals in the Netherlands, Belgium, Germany and Australia, we are committed to measuring up to 2000 patients. The study will run from 2023 to 2027.
Orikami offers its platform with which cognitive measurements in patients will be made on a continuous basis. Patients measure themselves at home (remote monitoring) so that a comprehensive picture is created of the cognitive development over time and, in particular, whether the drug Dapagliflozin may have a positive effect on the patient’s cognition.
The Orikami team is proud of this participation and looking forward to this collaboration in the coming years.
More information about the study can be read here.